Heather Payne
University College London
CancerInternal medicineRadiologySurgeryOncologyPsychologyLateralityCognitive psychologyProstateLanguage productionBrachytherapyAndrogen deprivation therapyCancer registryDiseaseChild protectionProstatectomyProstate cancerToxicitySemantic fluencyConfidence intervalRadiation therapyGeneral surgeryMedicineLateralization of brain function
57Publications
11H-index
710Citations
Publications 56
Newest
#1William Kinnaird (UCL: University College London)H-Index: 1
#2Ami Mehta (UCL: University College London)
Last. Susan Catt (University of Sussex)H-Index: 13
view all 6 authors...
Androgen deprivation therapy (ADT) is one of the main treatments for prostate cancer. Short-term ADT of between 6 months and 3 years is often used in combination with radiotherapy to treat localised and locally advanced prostate cancer. Permanent or intermittent ADT is used to treat metastatic disease. Hot flushes affect 44-80% of men undergoing ADT for prostate cancer, with around 27% saying they are the most distressing side effect.1 A recent UK survey found 30.7% of men treated with ADT repor...
Source
#1Amit Bahl (University Hospitals Bristol NHS Foundation Trust)H-Index: 24
#2Amarnath Challapalli (University Hospitals Bristol NHS Foundation Trust)H-Index: 14
Last. Heather Payne (UCL: University College London)H-Index: 11
view all 4 authors...
AIM To understand the awareness and use of rectal spacers for prostate cancer patients undergoing radical radiotherapy in the UK. METHODS An expert-devised online questionnaire was completed by members of the British Uro-oncology Group (BUG). RESULTS Sixty-three specialists completed the survey (50% of BUG members at that point in time). Only 37% had used rectal spacers, mostly for private patients or those with pre-existing bowel conditions. However, many (68%) would like to use these devices i...
Source
#1William Kinnaird (UCL: University College London)H-Index: 1
#2Vaidehi Ks Konteti (UCL: University College London)
Last. Heather Payne (UCL: University College London)H-Index: 11
view all 5 authors...
Source
#1Jonathan Aning (North Bristol NHS Trust)H-Index: 6
#2Matthew G. Parry (RCS: Royal College of Surgeons of England)H-Index: 8
Last. Noel W. Clarke (University of Salford)H-Index: 71
view all 8 authors...
OBJECTIVES To evaluate the accuracy and completeness of surgeon-reported radical prostatectomy outcome data across a national health system by comparison with a national dataset gathered independently from clinicians directly involved in patient care. PATIENTS AND METHODS Data submitted by surgeons to the British Association of Urological Surgeons (BAUS) radical prostatectomy audit for all men undergoing radical prostatectomy between 2015 and 2016 were assessed by cross linkage to the National P...
Source
#1Matthew G. Parry (RCS: Royal College of Surgeons of England)H-Index: 8
#2Julie Nossiter (RCS: Royal College of Surgeons of England)H-Index: 8
Last. Ajay Aggarwal (Guy's and St Thomas' NHS Foundation Trust)H-Index: 18
view all 12 authors...
Purpose External beam radiation therapy (EBRT) with brachytherapy boost reduces cancer recurrence in patients with prostate cancer compared with EBRT monotherapy. However, randomized controlled trials or large-scale observational studies have not compared brachytherapy boost types directly. Methods and Materials This observational cohort study used linked national cancer registry data, radiation therapy data, administrative hospital data, and mortality records of 54,642 patients with intermediat...
3 CitationsSource
#1Asim Afaq (UCL: University College London)H-Index: 14
#2Heather Payne (UCL: University College London)H-Index: 11
Last. Jamshed Bomanji (UCL: University College London)H-Index: 52
view all 15 authors...
Objectives: To assess the safety and clinical impact of a novel, kit-based formulation of 68Ga‐THP PSMA positron emission tomography/computed tomography (PET/CT) when used to guide the management of patients with prostate cancer (PCa). Methods: Patients were prospectively recruited in to one of: Group A: high-risk untreated prostate cancer; Gleason score >4+3, or PSA >20 ng/mL or clinical stage >T2c. Group B: biochemical recurrence (BCR) and eligible for salvage treatment after radical prostatec...
Source
#1Amit Bahl (University Hospitals Bristol NHS Foundation Trust)H-Index: 24
#2Simon J. Crabb (University of Southampton)H-Index: 30
Last. Heather Payne (UCL: University College London)H-Index: 11
view all 8 authors...
AIM To explore the practice and views of uro-oncologists in the United Kingdom regarding their use of chemotherapy and androgen receptor-targeted agents (ARTAs) in patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC). METHODS An expert-devised paper or online questionnaire was completed by members of the British Uro-oncology Group. RESULTS All respondents stated that they would offer patients with newly diagnosed mHSPC docetaxel and androgen deprivation therapy (ADT...
Source
#1Matthew G. Parry (Lond: University of London)H-Index: 8
#2Julie Nossiter (RCS: Royal College of Surgeons of England)H-Index: 8
Last. Ajay Aggarwal ('KCL': King's College London)H-Index: 18
view all 10 authors...
Abstract Background and purpose Little is known about the functional outcomes and health-related quality of life (HRQoL) following external beam radiation therapy (EBRT) combined with a high-dose rate brachytherapy boost (EBRT-BB) for the treatment of prostate cancer. We aimed to compare patient-reported outcomes of EBRT to those of EBRT-BB. Methods and materials Patients diagnosed with intermediate-risk, high-risk or locally advanced prostate cancer (April 2014 to September 2016), who received ...
Source
#1Heather PayneH-Index: 11
#2Dorothy BishopH-Index: 1
view all 7 authors...
#1Chris ParkerH-Index: 83
#2Noel W. Clarke (University of Salford)H-Index: 71
Last. Matthew R. SydesH-Index: 70
view all 48 authors...
Summary Background The optimal timing of radiotherapy after radical prostatectomy for prostate cancer is uncertain. We aimed to compare the efficacy and safety of adjuvant radiotherapy versus an observation policy with salvage radiotherapy for prostate-specific antigen (PSA) biochemical progression. Methods We did a randomised controlled trial enrolling patients with at least one risk factor (pathological T-stage 3 or 4, Gleason score of 7–10, positive margins, or preoperative PSA ≥10 ng/mL) for...
48 CitationsSource